Acute Heart Failure (AHF) Therapeutics

World Market Report

MCP-6845

EXECUTIVE ENGAGEMENTS

POOL

5733
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

918
Interactions with Platform & by Email

PARTICIPANTS

172
Unique # Participated

VALIDATIONS

37
Responses Validated*

COMPANIES

93
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2023

TABLES

202

PAGES

299

EDITION

19

PRICE

USD 5450

CODE

MCP-6845


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Acute Heart Failure (AHF) Therapeutics Market to Reach $2.9 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2022-2030. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 2.6% CAGR and reach US$762.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the B-Blockers segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $642.1 Million, While China is Forecast to Grow at 8.3% CAGR
The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$642.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 8.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -1.4% and -0.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately -1.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433.4 Million by the year 2030.

SELECT PLAYERS

Bayer AG; Bristol-Myers Squibb Company; Cardiorentis AG; CVie Therapeutics Limited; Cytokinetics, Inc.; Merck & Co., Inc.; Novartis AG; Orion Corporation; PhaseBio Pharmaceuticals, Inc.

SEGMENTS

» Product Type (Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics, Other Product Types) » End-Use (Home Care, Hospitals, Clinics, Other End-Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Market Outlook
Recent Market Activity
Sizing the AHF Market
Acute Heart Failure - An Overview of the Disease and Available Therapeutics
Diuretics and Vasodilators - The First Line Therapy for AHF
Other Known Drugs for AHF - Lower Efficacy Thwarts Use
Acute Heart Failure (AHF) Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Cardiorentis AG (Switzerland)
CVie Therapeutics Limited (Taiwan)
Cytokinetics, Inc. (USA)
Merck & Co. (USA)
Novartis AG (Switzerland)
Orion Corporation (Finland)
PhaseBio Pharmaceuticals, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Conventional Therapies Leave Considerable Unmet Needs
Novel Treatments Offer a Ray of Hope
Key AHF Therapeutics in the Pipeline
Serelaxin Nears Trial Readout form RELAX-AHF-2
Ularitide - A Novel Drug in Development for AHF
The Litany of Drug Failures Expands, Emphasis on Prevention Grows
Other Promising Drugs under Development
Research Findings
Kidney Dysfunction - Predictor of Acute Heart failure
Genetic Influence on Heart Disease among African Americans
Higher Body Mass Index - A Key Risk Factor for AHF
Supplemental Oxygen Therapy May not be for All Cases of AHF
Macro Growth Drivers
Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Cardiac Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Cardiac Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027
World Acute Heart Failure (AHF) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
UNITED STATES
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
JAPAN
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
CHINA
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
EUROPE
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2021 & 2027
Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
FRANCE
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
GERMANY
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
UNITED KINGDOM
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
SPAIN
Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
RUSSIA
Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
ASIA-PACIFIC
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
AUSTRALIA
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
INDIA
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
LATIN AMERICA
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
ARGENTINA
Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
BRAZIL
Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
MEXICO
Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
REST OF LATIN AMERICA
Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
MIDDLE EAST
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
IRAN
Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
ISRAEL
Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
SAUDI ARABIA
Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
UNITED ARAB EMIRATES
UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
REST OF MIDDLE EAST
Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027
AFRICA
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027
Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com